Objective To investigate the association between serum insulin-like growth factor-1 （IGF-1） and Parkinson's disease （PD） with osteoporosis （OP）.Methods A retrospective analysis was performed for the clinical data of 105 patients with PD （PD group） and 78 healthy controls （HC group）， and general clinical data and serum IGF-1 level were compared between the two groups. Dual-energy X-ray absorptiometry was used to measure bone mineral density （BMD）， and then the patients with PD were divided into PD+OP group with 50 patients and non-OP PD group with 55 patients； general clinical data and serum IGF-1 level were compared between the two groups. The Pearson correlation analysis was used to investigate the correlation of serum IGF-1 level with lumbar vertebral BMD and left femoral neck BMD， and the multivariate logistic regression analysis was used to investigate the risk factors for PD in patients with OP.Results Compared with the HC group， the PD group had a significant reduction in serum IGF-1 level （P<0.05）. The Pearson correlation analysis showed that serum IGF-1 level was positively correlated with lumbar vertebral BMD （r=0.653， P<0.001） and left femoral neck BMD （r=0.625， P<0.001）. The multivariate logistic regression analysis showed that the reductions in serum IGF-1 and uric acid （UA） and the increase in H-Y staging were risk factors for PD in patients with OP （P<0.05）.Conclusions The reductions in serum IGF-1 and UA and the increase in H-Y staging are closely associated with PD in patients with OP， and increasing the serum levels of IGF-1 and UA may be a potential therapeutic method for this disorder. ［Journal of International Neurology and Neurosurgery, 2023, 50(6): 7-12］